Dr. Bhishamjit Singh Chera, MD

Dr. Chera practices at MUSC Physicians in Mount Pleasant, South Carolina.

Dr. Chera's NPI, 1265522593, was assigned on October 16, 2006. Dr. Chera graduated from Medical University of South Carolina College of Medicine in 2004. Dr. Chera holds South Carolina license 27213.

Dr. Chera's primary practice is MUSC Physicians, at 1208 2 Island Ct, Mount Pleasant, SC 29466 in Charleston County. The practice phone is (803) 286-4666.

Dr. Chera's primary practice is MUSC Physicians in Mount Pleasant, South Carolina. Dr. Chera is also affiliated with UNC Hospitals. The medical group on file is MUSC Health. Dmand AI also links Dr. Chera to 1 more hospital, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chera practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Chera's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Chera's licenses on file in 2 states: South Carolina and North Carolina.

CMS data shows 2,151 Medicare services from Dr. Chera across 13 procedure codes in 2024, for 161 Medicare patients. Medicare paid $139,330 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 161 Medicare patients who saw Dr. Chera in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 1.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chera's median patient age at 68, with 27% women.

In 2024, Dr. Chera wrote 145 Medicare Part D claims for 59 patients. 85% of them were for generic drugs. CMS names the drug for 63 of them, across 3 drugs with 11 or more claims each, at $881 in total drug cost. In 2023, CMS named 48 claims across 2 drugs.

Dr. Chera accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 114 papers to Dr. Chera, published from 2010 to 2025. 2017 was the busiest year, with 12. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Squamous Cell Carcinoma of Head and Neck. Dr. Chera has published most often in Pract Radiat Oncol. Dr. Chera's most frequent co-authors are Lawrence B. Marks, MD, Trevor G. Hackman, MD and Adam Mikial Zanation, MD.

Dmand AI links Dr. Chera to 7 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Oropharyngeal Neoplasms, Pharyngeal Neoplasms and Salivary Gland Neoplasms. UNC Lineberger Comprehensive Cancer Center sponsors the most, 5.

CMS Open Payments shows 8 general payments to Dr. Chera from 5 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 94% of the total. Stryker Corporation paid the most, $253.

Dr. Chera graduated from Medical University of South Carolina College of Medicine in 2004.